Proliferative Diabetic Retinopathy Market

Proliferative Diabetic Retinopathy Market (Drug Class: Anti-VEGF Agents and Corticosteroids; and Mode of Administration: Injectable, Oral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031

Global Proliferative Diabetic Retinopathy Market Outlook 2031

  • The industry was valued at US$ 2.5 Bn in 2022
  • It is estimated to grow at a CAGR of 8.5% from 2023 to 2031 and reach US$ 5.2 Bn by the end of 2031

Analyst Viewpoint

Increase in prevalence of diabetes and technological advancements in diabetic retinopathy surgical instruments are fueling the proliferative diabetic retinopathy market size. Proliferative diabetic retinopathy is one of the leading vision impairments in the geriatric population, thereby requiring early diagnosis and effective treatment. Growth in geriatric population across the globe is propelling the market expansion.

Leading companies in the industry focus on introducing precise drugs and therapies to ensure disease diagnosis at an initial stage and reduce the risk of vision loss. Technological advancements in healthcare sector offer lucrative proliferative diabetic retinopathy market opportunities for the companies operating in this business. Moreover, they conduct clinical trials to receive product approvals from authorized organizations to introduce new products in global markets.

Proliferative Diabetic Retinopathy Market

Market Introduction

Proliferative Diabetic Retinopathy (PDR) is an advanced stage of diabetic retinopathy, a complication of diabetes that affects the eyes by damaging the blood vessels in the retina. Growth of abnormal blood vessels in the retina can lead to serious vision problems and even blindness if left untreated. High blood pressure, high cholesterol levels, and poorly controlled diabetes may lead to these vision impairments. Proliferative retinopathy can lead to complications such as vitreous hemorrhage and retinal detachment.

Laser therapy to shrink and destroy abnormal blood vessels and surgery are some of the common treatments for proliferative diabetic retinopathy. Surgical interventions for proliferative retinopathy include a vitrectomy procedure to remove blood and scar tissue from the vitreous, and panretinal photocoagulation to preserve vision and prevent complications.

Increase in Prevalence of Diabetes Fostering Proliferative Diabetic Retinopathy Market Growth

Adoption of sedentary lifestyles, lack of physical activities, poor diets, and high consumption of processed food increase the risk of various chronic diseases, especially diabetes. Type I and Type II diabetes may cause microvascular complications, leading to proliferative diabetic retinopathy. These complications can progress to sight-threatening stages, further causing blindness and visual impairment if not treated. Thus, rise in prevalence of diabetes among the population is contributing to the growth of the proliferative diabetic retinopathy industry.

According to the Centers for Disease Control and Prevention, diabetic retinopathy is projected to affect 16 million people with diabetes by 2050 in the U.S. Early detection and treatment can help avoid more than 90% of vision loss cases and intensive management of blood glucose levels can reduce the risk of diabetic retinopathy by 27%.

As per the proliferative diabetic retinopathy market forecast, growth in geriatric population across the globe is likely to propel market dynamics in the near future. The risk of developing diabetic retinopathy is higher in geriatric patients, especially those with a longer duration of diabetes. Geriatric patients may experience delays in the diagnosis of diabetic retinopathy due lack of awareness and delayed eye screenings.

Technological Advancements in Diabetic Retinopathy Surgical Instruments Fostering Market Statistics

Early detection, screening, and treatment help reduce the risk of proliferative diabetic retinopathy. Diagnostic advancements in diabetic eye care, such as micro-incision surgery, robot-assisted surgery, endoscopic visualization, sutureless surgery, and 3D visualization techniques help surgeons to diagnose and provide treatments efficiently. Hence, increase in adoption of advanced technologies in diabetic retinopathy surgical instruments is driving the proliferative diabetic retinopathy market revenue.

Moreover, increase in investments in gene therapy research in diabetic retinopathy is fueling the market progress. Gene therapy focuses on inhibiting abnormal vascular growth and modulating inflammation to restrict the progression of diabetic retinopathy. Healthcare organizations and research institutes are focusing on developing innovative gene therapies to effectively provide treatment for vision impairments.

Regional Outlook

According to the latest proliferative diabetic retinopathy market analysis, North America dominated the global market in 2022. Increase in awareness regarding diabetes and well-established healthcare facilities are likely to propel the proliferative diabetic retinopathy industry share during the forecast period. Favorable government initiatives and practitioner awareness are promoting eye care among the diabetic population.

According to the National Institutes of Health, about 440 million people in the age group 20-79 years are estimated to be suffering from diabetes mellitus worldwide which is around 7.7% by the year 2030. Thus, increase in prevalence of diabetes among people is augmenting market development in this region.

Analysis of Key Players in Proliferative Diabetic Retinopathy Industry

As per the latest proliferative diabetic retinopathy market trends, leading companies in the market are focusing on new product launches and drug development practices to improve their product portfolio. They are conducting clinical trials to receive approvals from government organizations to ensure the effectiveness and efficiency of the products.

Some of the players in the industry are Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, and Intas Pharmaceuticals Ltd.

These companies have been profiled in the proliferative diabetic retinopathy market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Key Developments

  • In August 2023, Regeneron Pharmaceuticals, Inc., a leading biotechnology company received the U.S. Food and Drug Administration (FDA) approval for EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), and wet Age-related Macular Degeneration (wAMD).
  • In June 2023, Eyenuk, a global Artificial Intelligence (AI) medical technology and services company received FDA clearance for its Topcon NW400 retinal camera with its EyeArt AI system for the autonomous AI detection of diabetic retinopathy.

Proliferative Diabetic Retinopathy Market Snapshot

Attribute Detail
Market Size in 2022 US$ 2.5 Bn
Market Forecast (Value) in 2031 US$ 5.2 Bn
Growth Rate (CAGR) 8.5%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Class
    • Anti-VEGF Agents
    • Corticosteroids
  • Mode of Administration
    • Injectable
    • Oral
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • Genentech, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Merck KGaA
  • Cipla Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Alimera Sciences
  • Intas Pharmaceuticals Ltd.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global proliferative diabetic retinopathy market in 2022?

It was valued at US$ 2.5 Bn in 2022

How is the proliferative diabetic retinopathy sector expected to grow by 2031?

It is projected to register a CAGR of 8.5% from 2023 to 2031

What are the key factors driving the demand for proliferative diabetic retinopathy?

Increase in prevalence of diabetes and technological advancements in diabetic retinopathy surgical instruments

Which was the most lucrative region in the proliferative diabetic retinopathy industry in 2022?

North America was the most lucrative region in 2022

Who are the prominent players in the proliferative diabetic retinopathy sector?

Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, and Intas Pharmaceuticals Ltd

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Proliferative Diabetic Retinopathy Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product/Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. Anti-VEGF Agents

        6.3.2. Corticosteroids

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Mode of Administration

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Mode of Administration, 2017–2031

        7.3.1. Injectable

        7.3.2. Oral

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by Mode of Administration

8. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017–2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Proliferative Diabetic Retinopathy Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Drug Class, 2017–2031

        10.3.1. Anti-VEGF Agents

        10.3.2. Corticosteroids

    10.4. Market Value Forecast, by Mode of Administration, 2017–2031

        10.4.1. Injectable

        10.4.2. Oral

        10.4.3. Others

    10.5. Market Value Forecast, by Distribution Channel, 2017–2031

        10.5.1. Hospital Pharmacies

        10.5.2. Retail Pharmacies

        10.5.3. Online Pharmacies

    10.6. Market Value Forecast, by Country, 2017–2031

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Drug Class

        10.7.2. By Mode of Administration

        10.7.3. By Distribution Channel

        10.7.4. By Country

11. Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Drug Class, 2017–2031

        11.3.1. Anti-VEGF Agents

        11.3.2. Corticosteroids

    11.4. Market Value Forecast, by Mode of Administration, 2017–2031

        11.4.1. Injectable

        11.4.2. Oral

        11.4.3. Others

    11.5. Market Value Forecast, by Distribution Channel, 2017–2031

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Drug Class

        11.7.2. By Mode of Administration

        11.7.3. By Distribution Channel

        11.7.4. By Country/Sub-region

12. Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Drug Class, 2017–2031

        12.3.1. Anti-VEGF Agents

        12.3.2. Corticosteroids

    12.4. Market Value Forecast, by Mode of Administration, 2017–2031

        12.4.1. Injectable

        12.4.2. Oral

        12.4.3. Others

    12.5. Market Value Forecast, by Distribution Channel, 2017–2031

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. China

        12.6.2. Japan

        12.6.3. India

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis

        12.7.1. By Drug Class

        12.7.2. By Mode of Administration

        12.7.3. By Distribution Channel

        12.7.4. By Country/Sub-region

13. Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Drug Class, 2017–2031

        13.3.1. Anti-VEGF Agents

        13.3.2. Corticosteroids

    13.4. Market Value Forecast, by Mode of Administration, 2017–2031

        13.4.1. Injectable

        13.4.2. Oral

        13.4.3. Others

    13.5. Market Value Forecast, by Distribution Channel, 2017–2031

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Drug Class

        13.7.2. By Mode of Administration

        13.7.3. By Distribution Channel

        13.7.4. By Country/Sub-region

14. Middle East & Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, by Drug Class, 2017–2031

        14.3.1. Anti-VEGF Agents

        14.3.2. Corticosteroids

    14.4. Market Value Forecast, by Mode of Administration, 2017–2031

        14.4.1. Injectable

        14.4.2. Oral

        14.4.3. Others

    14.5. Market Value Forecast, by Distribution Channel, 2017–2031

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Drug Class

        14.7.2. By Mode of Administration

        14.7.3. By Distribution Channel

        14.7.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2022)

    15.3. Company Profiles

        15.3.1. Genentech, Inc.

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Novartis AG

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Regeneron Pharmaceuticals, Inc.

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Pfizer Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Merck KGaA

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Cipla Inc.

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. AbbVie Inc.

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Bausch Health Companies Inc.

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Santen Pharmaceutical Co., Ltd.

            15.3.9.1. Company Overview

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Alimera Sciences

            15.3.10.1. Company Overview

            15.3.10.2. Product Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

        15.3.11. Intas Pharmaceuticals Ltd.

            15.3.11.1. Company Overview

            15.3.11.2. Product Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Financial Overview

            15.3.11.5. Strategic Overview

List of Tables

Table 01: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 03: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 08: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 12: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 16: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 20: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 24: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Drug Class, 2022

Figure 03: Global Proliferative Diabetic Retinopathy Market Value Share, by Drug Class, 2022

Figure 04: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Mode of Administration, 2022

Figure 05: Global Proliferative Diabetic Retinopathy Market Value Share, by Mode of Administration, 2022

Figure 06: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Proliferative Diabetic Retinopathy Market Value Share, by Distribution Channel, 2022

Figure 08: Global Proliferative Diabetic Retinopathy Market Value Share, by Region, 2022

Figure 09: Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 11: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 12: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 13: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023-2031

Figure 14: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 15: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Figure 16: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country, 2022 and 2031

Figure 21: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 22: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 23: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 24: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 25: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 26: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 32: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 33: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 34: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 35: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 40: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 41: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 42: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 44: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 49: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 50: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 51: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 52: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 53: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 58: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 59: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 60: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 61: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 62: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved